Zynerba Pharmaceuticals Dirección
Dirección controles de criterios 3/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Armando Anido
Chief Executive Officer (CEO)
US$1.9m
Compensación total
| Porcentaje del salario del CEO | 33.6% |
| Permanencia del CEO | 9yrs |
| Participación del CEO | 1.9% |
| Permanencia media de la dirección | 6.8yrs |
| Promedio de permanencia en la Junta Directiva | 8.2yrs |
Actualizaciones recientes de la dirección
Recent updates
Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?
Mar 01
Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?
Nov 11Zynerba stock rises on US patent for cannabidiol Zygel's use for Fragile X syndrome
Oct 06Zynerba Pharmaceuticals GAAP EPS of -$0.24 misses by $0.01
Aug 10We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth
Jul 22Zynerba inks equity funding contract of up to $20M with Lincoln Park Capital
Jul 21Here's Why We're Watching Zynerba Pharmaceuticals' (NASDAQ:ZYNE) Cash Burn Situation
Mar 23We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth
Dec 02We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth
May 27Zynerba Pharma shares slip 10% on Zygel update in Fragile X syndrome
Dec 17Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?
Nov 23
Zynerba Pharmaceuticals EPS beats by $0.12
Nov 09Zynerba Zygel Remains A Huge Part Of The Company's Pipeline Despite Setback
Oct 29Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | -US$38m |
| Mar 31 2023 | n/a | n/a | -US$37m |
| Dec 31 2022 | US$2m | US$633k | -US$35m |
| Sep 30 2022 | n/a | n/a | -US$36m |
| Jun 30 2022 | n/a | n/a | -US$38m |
| Mar 31 2022 | n/a | n/a | -US$38m |
| Dec 31 2021 | US$2m | US$603k | -US$37m |
| Sep 30 2021 | n/a | n/a | -US$38m |
| Jun 30 2021 | n/a | n/a | -US$37m |
| Mar 31 2021 | n/a | n/a | -US$47m |
| Dec 31 2020 | US$1m | US$585k | -US$51m |
| Sep 30 2020 | n/a | n/a | -US$52m |
| Jun 30 2020 | n/a | n/a | -US$45m |
| Mar 31 2020 | n/a | n/a | -US$36m |
| Dec 31 2019 | US$1m | US$568k | -US$33m |
| Sep 30 2019 | n/a | n/a | -US$30m |
| Jun 30 2019 | n/a | n/a | -US$36m |
| Mar 31 2019 | n/a | n/a | -US$37m |
| Dec 31 2018 | US$2m | US$568k | -US$40m |
| Sep 30 2018 | n/a | n/a | -US$40m |
| Jun 30 2018 | n/a | n/a | -US$41m |
| Mar 31 2018 | n/a | n/a | -US$37m |
| Dec 31 2017 | US$2m | US$552k | -US$32m |
| Sep 30 2017 | n/a | n/a | -US$31m |
| Jun 30 2017 | n/a | n/a | -US$28m |
| Mar 31 2017 | n/a | n/a | -US$26m |
| Dec 31 2016 | US$901k | US$536k | -US$23m |
Compensación vs. Mercado: La compensación total de Armando($USD1.88M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD677.87K).
Compensación vs. Ingresos: La compensación de Armando ha sido consistente con los resultados de la empresa en el último año.
CEO
Armando Anido (65 yo)
9yrs
Permanencia
US$1,881,402
Compensación
Mr. Armando Anido, MBA, has been the Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, Inc. since October 2014. Mr. Anido has been an Independent Director of SCYNEXIS, Inc. since January 21,...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & CEO | 9yrs | US$1.88m | 1.94% $ 1.3m | |
| President | 9yrs | US$1.38m | 1.18% $ 775.1k | |
| CFO & VP of Corporate Development (Leave of Absence) | 7.1yrs | US$1.26m | 0.75% $ 491.5k | |
| VP, Corporate Controller & Interim CFO | 6.6yrs | sin datos | 0.17% $ 111.2k | |
| Chief Legal Officer & Corporate Secretary | 1.7yrs | sin datos | 0.45% $ 295.1k | |
| Vice President of Human Resources | 5.6yrs | sin datos | sin datos |
6.8yrs
Permanencia media
59yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ZYNE es experimentado (6.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & CEO | 9yrs | US$1.88m | 1.94% $ 1.3m | |
| Independent Director | 8.2yrs | US$107.50k | 0.15% $ 98.5k | |
| Independent Director | 8.2yrs | US$105.00k | 0.15% $ 98.5k | |
| Lead Independent Director | 8.2yrs | US$135.00k | 0.15% $ 98.5k | |
| Independent Director | 5.5yrs | US$102.50k | 0.16% $ 105.0k | |
| Independent Director | 8.2yrs | US$110.00k | 0.15% $ 98.5k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | 8yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | 7yrs | sin datos | sin datos | |
| Independent Director | 4.7yrs | US$100.00k | 0.15% $ 98.5k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos |
8.2yrs
Permanencia media
65yo
Promedio de edad
Junta con experiencia: La junta directiva de ZYNE se considera experimentada (8.2 años de antigüedad promedio).